Physician profile
Jay L Viernes
NPI 1053399477
$8,433.20
in general payments reported to CMS, 2019-2025
16 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,382 · 2020: $677 · 2021: $908 · 2022: $1,309 · 2023: $1,333 · 2024: $885 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,061 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,061.29 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,506.77 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $2,000.50 | 2019-2025 | |
| Abbvie INC. | $782.87 | 2019-2025 | Skyrizi |
| Genzyme Corporation | $554.99 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $382.98 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $300.60 | 2022-2024 | Vtama |
| Ucb, INC. | $279.74 | 2019-2024 | Bimzelx |
| Pfizer INC. | $142.85 | 2019-2021 | |
| Lilly USA, LLC | $94.87 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $92.80 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $91.24 | 2019-2025 | Ilumya |
| Sanofi-Aventis U.S. LLC | $79.99 | 2020 | |
| Amgen INC. | $46.92 | 2021-2024 | Otezla |
| Mayne Pharma Commercial LLC | $31.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.88 | 2024 | Sotyktu |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $22.11 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Viernes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.